Patents by Inventor Philippe Erbs
Philippe Erbs has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190330655Abstract: The present invention relates to an oncolytic virus encoding a cytidine deaminase (CDAse) polypeptide, a composition comprising it, as well as their use for prophylactic or therapeutic purposes, and more particularly for the treatment of cancer. The present invention also provides a method for treating a disease or a pathologic condition comprising the administration of such an oncolytic virus or composition thereof and a process for preparing such an oncolytic virus.Type: ApplicationFiled: December 21, 2017Publication date: October 31, 2019Applicant: TRANSGENE SAInventors: Philippe ERBS, Johann FOLOPPE
-
Patent number: 9884080Abstract: The present invention relates to a poxvirus comprising a defective F4L and/or I4L gene, to composition comprising such poxvirus and to the methods and use of such compositions and poxviruses for therapeutic purposes, and more particularly for the treatment of cancer.Type: GrantFiled: February 27, 2013Date of Patent: February 6, 2018Assignee: Transgene S.A.Inventors: Philippe Erbs, Johann Foloppe
-
Patent number: 9687515Abstract: The present invention relates to a poxvirus comprising a defective F4L and/or I4L gene, to composition comprising such poxvirus and to the methods and use of such compositions and poxviruses for therapeutic purposes, and more particularly for the treatment of cancer.Type: GrantFiled: April 10, 2014Date of Patent: June 27, 2017Assignee: Transgene S.A.Inventors: Philippe Erbs, Johann Foloppe
-
Patent number: 9180150Abstract: A poxvirus comprising a defective F2L gene and compositions comprising such poxvirus are useful for therapeutic purposes, and more particularly for the treatment of cancer.Type: GrantFiled: November 17, 2008Date of Patent: November 10, 2015Assignee: Transgene S.A.Inventors: Philippe Erbs, Johann Foloppe
-
Patent number: 9024003Abstract: The present invention notably relates to novel recombinant telomerase reverse transcriptases, nucleic acid molecules coding them, cells comprising said nucleic acid molecule and use of these cells for the production of substance of interest.Type: GrantFiled: January 5, 2007Date of Patent: May 5, 2015Assignee: Transgene S.A.Inventors: Philippe Erbs, Jean-Marc Balloul, Marina Kapfer, Nathalie Silvestre
-
Publication number: 20150017126Abstract: The present invention relates to a poxvirus comprising a defective F4L and/or I4L gene, to composition comprising such poxvirus and to the methods and use of such compositions and poxviruses for therapeutic purposes, and more particularly for the treatment of cancer.Type: ApplicationFiled: April 10, 2014Publication date: January 15, 2015Applicant: Transgene S.A.Inventors: Philippe ERBS, Johann Foloppe
-
Patent number: 8778328Abstract: A poxvirus other than NYVAC but comprising a defective F4L and/or I4L gene and compositions comprising such poxvirus are useful for therapeutic purposes, and more particularly for the treatment of cancer.Type: GrantFiled: November 17, 2008Date of Patent: July 15, 2014Assignee: Transgene S.A.Inventors: Philippe Erbs, Johann Foloppe
-
Publication number: 20130287737Abstract: The present invention relates to a poxvirus comprising a defective F4L and/or I4L gene, to composition comprising such poxvirus and to the methods and use of such compositions and poxviruses for therapeutic purposes, and more particularly for the treatment of cancer.Type: ApplicationFiled: February 27, 2013Publication date: October 31, 2013Applicant: TRANSGENE S.A.Inventors: Philippe Erbs, Johann Foloppe
-
Publication number: 20130244246Abstract: This invention relates to immortalized avian cells, and to the use of these cells for the production of viruses. The cells according to the invention are particularly useful for the production of recombinant viral vectors which can be used for the preparation of therapeutic and/or prophylactic compositions for the treatment of animals and more particularly humans.Type: ApplicationFiled: December 21, 2012Publication date: September 19, 2013Applicant: TRANSGENE S.A.`Inventors: Philippe Erbs, Marina Kapfer, Nathalie Silvestre
-
Patent number: 8513018Abstract: This invention relates to immortalized avian cells, including those deposited under accession numbers 09070701, 09070702, and 09070703 at the ECACC, and to the use of these cells for the production of viruses. The cells according to the invention are particularly useful for the production of recombinant viral vectors which can be used for the preparation of therapeutic and/or prophylactic compositions for the treatment of animals and more particularly humans.Type: GrantFiled: May 29, 2012Date of Patent: August 20, 2013Assignee: Transgene S.A.Inventors: Philippe Erbs, Marina Kapfer, Nathalie Silvestre
-
Patent number: 8470591Abstract: The present invention relates to a kit of parts comprising a nucleic acid sequence encoding a permease and a drug comprising one nucleobase moiety or a precursor thereof. The present invention further relates to a kit of parts comprising a precursor of a drug comprising a gene coding a permease and a nucleic acid sequence comprising a suicide gene. The present invention also relates to a vector comprising a gene coding a permease and a suicide gene.Type: GrantFiled: October 26, 2005Date of Patent: June 25, 2013Assignee: Transgene S.A.Inventor: Philippe Erbs
-
Publication number: 20130095557Abstract: This invention relates to immortalized avian cells, including those deposited under accession numbers 09070701, 09070702, and 09070703 at the ECACC, and to the use of these cells for the production of viruses. The cells according to the invention are particularly useful for the production of recombinant viral vectors which can be used for the preparation of therapeutic and/or prophylactic compositions for the treatment of animals and more particularly humans.Type: ApplicationFiled: June 29, 2011Publication date: April 18, 2013Applicant: TRANSGENE S.A.Inventors: Philippe Erbs, Marina Kapfer, Nathalie Silvestre
-
Publication number: 20130039891Abstract: The present invention relates to a poxvirus comprising a defective F4L and/or I4L gene, to composition comprising such poxvirus and to the methods and use of such compositions and poxviruses for therapeutic purposes, and more particularly for the treatment of cancer.Type: ApplicationFiled: September 15, 2012Publication date: February 14, 2013Applicant: TRANSGENE S.A.Inventors: Philippe ERBS, Johann Foloppe
-
Patent number: 8361788Abstract: Immortalized avian cell lines containing E1A nucleic acid sequences are useful for the production of viruses and are particularly useful for the production of recombinant viral vectors which can be employed for the preparation of therapeutic and/or prophylactic compositions for the treatment of animals and more particularly humans.Type: GrantFiled: July 2, 2008Date of Patent: January 29, 2013Assignee: Transgene S.A.Inventors: Philippe Erbs, Marina Kapfer, Nathalie Silvestre
-
Patent number: 8357531Abstract: This invention relates to immortalized avian cells, including those deposited under accession numbers 09070701, 09070702, and 09070703 at the ECACC, and to the use of these cells for the production of viruses. The cells according to the invention are particularly useful for the production of recombinant viral vectors which can be used for the preparation of therapeutic and/or prophylactic compositions for the treatment of animals and more particularly humans.Type: GrantFiled: July 2, 2010Date of Patent: January 22, 2013Assignee: Transgene S.A.Inventors: Philippe Erbs, Marina Kapfer, Nathalie Silvestre
-
Publication number: 20120238000Abstract: This invention relates to immortalized avian cells, including those deposited under accession numbers 09070701, 09070702, and 09070703 at the ECACC, and to the use of these cells for the production of viruses. The cells according to the invention are particularly useful for the production of recombinant viral vectors which can be used for the preparation of therapeutic and/or prophylactic compositions for the treatment of animals and more particularly humans.Type: ApplicationFiled: May 29, 2012Publication date: September 20, 2012Applicant: Transgene S.A.Inventors: Philippe Erbs, Marina Kapfer, Nathalie Silvestre
-
Patent number: 8257692Abstract: The present invention relates to a polypeptide possessing a CDase activity, characterized in that it is derived from a native CDase by addition of an amino acid sequence with the proviso that said polypeptide has no UPRtase or Thymidine Kinase activity.Type: GrantFiled: June 24, 2010Date of Patent: September 4, 2012Assignee: Transgene, S.A.Inventor: Philippe Erbs
-
Patent number: 8226954Abstract: The present invention relates to a polypeptide possessing a CDase activity, characterized in that it is derived from a native CDase by addition of an amino acid sequence with the proviso that said polypeptide has no UPRtase or Thymidine Kinase activity.Type: GrantFiled: June 24, 2010Date of Patent: July 24, 2012Assignee: Transgene S.A.Inventor: Philippe Erbs
-
Patent number: 8211421Abstract: The invention concerns a polypeptide having a uracil phosphoribosyl transferase (UPRTase) by mutation of one or several residues of the UPRTase. The invention also concerns a nucleotide sequence coding for the UPRTase mutant, a vector for expressing the latter, a viral particle, a host cell, and a composition containing them. The invention further concerns their therapeutic use and a treatment method using them. The invention is particularly useful in the context of therapy by suicide genes, in particular, for treating proliferative and infectious diseases.Type: GrantFiled: June 30, 2009Date of Patent: July 3, 2012Assignee: Transgene S.A.Inventors: Philippe Erbs, Richard Jund
-
Publication number: 20110059049Abstract: A poxvirus other than NYVAC but comprising a defective F4L and/or I4L gene and compositions comprising such poxvirus are useful for therapeutic purposes, and more particularly for the treatment of cancer.Type: ApplicationFiled: November 17, 2008Publication date: March 10, 2011Inventors: Philippe Erbs, Johann Foloppe